Q-omics provides the consensus-scored DUSP3 profile across patient tissues and cancer cell-line models. DUSP3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DUSP3 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, DUSP3 protein abundance shows 25,650 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, KICH, and HNSC as cancer lineages where DUSP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUSP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUSP3 survival associations across molecular data types. DUSP3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUSP3 RNA expression–survival associations across cancer types. High DUSP3 expression shows unfavorable associations in MESO, HNSC, CESC, BLCA and LGG, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DUSP3 RNA expression.
This table summarizes DUSP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 11. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DUSP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUSP3 shows lower tumor expression in KICH, BLCA, LUAD and LUSC and higher tumor expression in LIHC and KIRP. The KICH box plot shows higher DUSP3 RNA expression in normal versus tumor tissue (log2 FC = −0.951, t-test p < 0.001).
This table shows molecular features associated with DUSP3 in patient tissues and cancer cell lines. In patient samples, DUSP3 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, DUSP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
